morph tirzepatide Compounded FDA Says Compounded Tirzepatide Must

The timing of this order was unexpected due to the ongoing litigation between FDA and the Outsourcing Facilities Association (OFA) involving tirzepatide, though the decision was not

(PubMed) Gould JF, Treyvaud K, Yelland LN, et al

The medication is administered as a once-weekly subcutaneous injection, with a recommended starting dose of 2.5 mg for 4 weeks, then 5 mg, with stepwise escalation to a maximum of 15 mg as tolerated, according to the UK SmPC

Novo Nordisks CagriSema Achieves 22.7% Weight Loss In Obesity Trial, Shows Potential As Next-Gen Dual Hormone Therapy CagriSema shows 22.7% weight loss in REDEFINE 1 trial, setting a new benchmark in obesity treatment with dual hormone therapy